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ulmonary hypertension is defined as an increase inmean pulmonary arterial pressure25mmHg at rest
nd occurs in a majority of patients with heart failure. Diagnostic imaging targets the right ventricle and
hepulmonary vasculature.Althoughechocardiography is cost-effective for screeningand follow-up, right
eart catheterization is still mandatory to differentiate pre- from post-capillary disease and to directly
easure pressure and flow. An important goal is to rule out chronic thromboembolic pulmonary hyper-
ension. This diagnostic step can be achieved by perfusion scintigraphy, whereas computed tomography
nd cardiac magnetic resonance have become indispensable ancillary methods for the diagnostic alloca-
ion to other World Health Organization subtypes of pulmonary hypertension. (J Am Coll Cardiol Img
010;3:1287–95) © 2010 by the American College of Cardiology FoundationP
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orsulmonary hypertension is a hemodynamic and
athophysiological state that can be found in
ultiple clinical conditions and is defined as an
nvasively measured mean pulmonary arterial
ressure 25 mm Hg at rest (1). The fourth
orld Health Organization Symposium on
ulmonary Hypertension in Dana Point, Cal-
fornia, in 2008 provided an updated classifica-
ion (2) and recommendations for contempo-
ary diagnosis and treatment (3). Five subsets
ave been defined: group 1 as pulmonary arte-
ial hypertension (PAH), group 2 as pulmonary
ypertension due to left heart disease, group 3
s pulmonary hypertension due to lung diseases
nd/or hypoxia, group 4 as chronic thrombo-
mbolic pulmonary hypertension (1), and
roup 5 as pulmonary hypertension of other
auses. Pulmonary arterial hypertension is a
apidly progressive and fatal disease leading to
ight ventricular (RV) failure and death (4).
rom the *Department of Internal Medicine II, Division of Cardio
Department of Radiology, Medical University of Vienna, Vienn
urgery, Medical University of Vienna, Vienna, Austria. The auth
isclose.anuscript received July 15, 2010; revised manuscript received Augustrognosis is dependent on disease subtype, sex,
enal function, hemodynamics, World Health
rganization functional class, exercise capacity,
rain natriuretic peptide levels, pericardial ef-
usion by echocardiography, diffusion capacity
or carbon monoxide, and vital parameters at
iagnosis (5,6). Incidences are assumed to be as
ow as 2.4 cases per million for PAH and as
igh as 60% to 70% of all cases with systolic
nd/or diastolic left ventricular dysfunction. An
nvasively measured resting pulmonary capillary
edge pressure of 15 mm Hg has been used to
istinguish between pre- and post-capillary
ulmonary hypertension. This distinction is
ritical because post-capillary pulmonary hy-
ertension does not respond to treatments for
re-capillary pulmonary hypertension. Hence,
hen invasive pressure measurements are per-
ormed during right heart catheterization, cap-
llary wedge pressure measurements must be
, Medical University of Vienna, Vienna, Austria;
ustria; and the ‡Department of Cardiothoracic
have reported that they have no relationships to26, 2010, accepted September 17, 2010.
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1288xact, and because of the frequent technical diffi-
ulties encountered when trying to obtain reliable
edge curves, left ventricular end-diastolic pressure
hould be documented in parallel. Post-capillary
ulmonary hypertension (7) is an important subset
nd accounts for 50% of all cardiac complications
nd 19% of early deaths in a heart failure popula-
ion (8,9).
The early clinical signs and symptoms are scarce,
nd the majority of patients have advanced disease
ith World Health Organization functional classes
igher than III at first presentation (10). PAH
hould be considered in the differential diagnosis of
nexplained fatigue, exertional dyspnea, syncope,
ngina, and progressive limitation of exercise capac-
ty, particularly in patients without common cardio-
ascular or respiratory disorders.
The goal of imaging in pulmonary hypertension
s to establish the diagnosis and identify disease
ubsets. Because the main anatomic components of
he pulmonary circulation are the RV and the
pulmonary vasculature, those are ad-
dressed separately in this review.
Imaging of the Right Ventricle
RV function is affected at rest when50%
of pulmonary resistance vessels are dys-
functional (11,12). RV function is impor-
tant because it is a predictor of survival
(1,4,13). Due to its shape and location and
the load dependence of the ejection frac-
tion, accurate evaluation of RV function
emains challenging. The ultimate goal of imaging
f the RV is to replace invasive right heart cathe-
erization, which is currently the gold standard for
ssessing filling pressures, compartmental satura-
ions, and parameters of RV function.
chocardiography. Cutoffs for simple and advanced
chocardiographic techniques for the diagnosis and
ollow-up of pulmonary hypertension are summa-
ized in Tables 1 (14–20) and 2 (21–26). RV
unction reflects mechanical coupling between the
ight ventricle and the pulmonary artery (27). An
nlarged right ventricle may result from volume
verload or intrinsic systolic or diastolic dysfunction
r may be a sign of manifest pulmonary hyperten-
ion. Transthoracic echocardiography and Doppler
maging provide direct and easily accessible impor-
ant information on relative chamber sizes, left and
ight ventricular function and valvular abnormali-
ies; permit estimation of RV hemodynamics; and
on-re therefore essential for the workup of suspected oulmonary hypertension. The peak pressure gradi-
nt of tricuspid insufficiency is calculated as 4 
Doppler imaging–derived maximal tricuspid re-
urgitation velocity in meters) squared. Based on
his result, systolic pulmonary arterial pressure is
stimated by adding the estimated right atrial pres-
ure in millimeters of mercury (mm Hg). Correla-
ions between echocardiography/Doppler imaging
nd invasive measurements of systolic pulmonary
rterial pressure are high, with r values ranging from
.57 to 0.93 (3). An estimated systolic pulmonary
rterial pressure of 50 mm Hg has been set as an
rbitrary cutoff in symptomatic patients to justify
nvasive evaluation (3) (Table 1).
Although several further Doppler imaging–based
alculations have been proposed (28), none of them,
ncluding estimates of pulmonary vascular resis-
ance (29,30) (Table 2), has yet helped circumvent
nvasive evaluations. However, the presence of a
ericardial effusion has been confirmed as a predic-
or of outcome (6,31). In addition, echocardio-
raphic parameters allow monitoring of medical
reatment (32) or outcomes after pulmonary endar-
erectomy (33). Recent data (34) suggest that di-
inished systolic longitudinal deformation reflects
he degree of RV dysfunction (Fig. 1, Online
ideos 1 to 4). Three-dimensional (3D) echocar-
iography shows promise for measuring RV vol-
mes and function compared with cardiac magnetic
esonance (CMR) (35), but more experience is
eeded.
MR. The current diagnostic value of CMR was
ecently critically reviewed (36). CMR provides
nformation on RV size, morphology and function,
nterventricular septal configuration, volumes and
ass, and the left-right delay in myocardial short-
ning (37) and permits the direct assessment of
orward and regurgitant flow, stroke volume, pul-
onary arterial distensibility, and RV mass (38,39).
ncreased RV end-diastolic volume may be the
ost appropriate marker for progressive RV failure
40). The reproducibility of CMR-derived param-
ters of ventricular function and mass is superior to
-dimensional echocardiography (41) and makes
MR useful for follow-up.
maging of the Pulmonary Vasculature
hest X-ray. Although of low sensitivity and speci-
city, a plain chest X-ray film can reveal significant
ulmonary vascular pathology (42) by illustrating
essel displacement and hyper- or hypovascularityB B R E V I A T I O N S
N D A C R O N YM S
MR cardiac magnetic
esonance
T computed tomography
AH pulmonary arterial
ypertension
V right ventricular
/Q radionuclide ventilatif the lungs.
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1289adioisotope ventilation–perfusion scanning. For di-
gnosis of acute pulmonary embolism (43), com-
uted tomography (CT) is the widely accepted
ethod of choice and has largely replaced planar
adionuclide ventilation-perfusion scanning (V/Q).
y contrast, V/Q is the main imaging modality to
ook for chronic thromboembolic pulmonary hyper-
ension (7) (Fig. 2) (44) because of its superior
ensitivity compared with that of CT (45–49)
Table 3). The criterion with which to diagnose
hronic thromboembolic pulmonary hypertension
n a V/Q scan is at least 1 larger defect (i.e.,
omposing at least half a segment) after a minimum
f 3 months of effective anticoagulation. V/Q has
0% to 100% sensitivity and 94% to 100% specific-
ty for the diagnosis (Table 3). Potential pitfalls are
mall, matched defects or nonsegmental perfusion
Table 1. Comparison of Cutoffs of Simple Echocardiographic Me
Pulmonary Hypertension
Echocardiographic Measurement Cutoff
Peak velocity of tricuspid regurgitation 3.4 m/s
2.9 m/s
Pulmonary ﬂow acceleration time of
RV ejection into the pulmonary artery
93 ms
Tricuspid annular plane systolic excursion 18 mm
Tricuspid annular tissue Doppler
systolic velocity
12 cm/s
10 cm/s
PH  pulmonary hypertension; PVR  pulmonary vascular resistance; RV  rig
Table 2. Comparison of Cutoffs of Advanced Echocardiographic
Pulmonary Hypertension
Echocardiographic Measurement Cut
Tricuspid annular DTI velocity time integral 2.5 cm
Continuous or pulsed Doppler of
pulmonary regurgitation
4  V2  RAP
sHVF sHVF VTI/(sHVF VTI
RV myocardial performance index
(Tei index) (IVRT  IVCT)/RVET
0.36
Pulmonary vascular capacitance (stroke
volume/pulse pressure)
3.0 ml/mm Hg de
2-dimensional strain of the basal segment
of the RV free wall
10% systolic longi
deformation
GPSS and LPSS Decrease in RV ejec
(Pulmonary ejection period/pulmonary
acceleration time) divided by RV total
systolic time
2.6
Pulsed Doppler early diastolic tricuspid
inﬂow/tissue Doppler early diastolic
myocardial velocity at the tricuspid
lateral annulus ETr/E=Tr
6
dHVF diastolic hepatic venous ﬂow; DTI Doppler tissue imaging; GPSS glo
relaxation time; LPSS  longitudinal peak systolic strain; mPAP  mean pulmo
time; sHVF  systolic hepatic venous ﬂow; VTI  velocity time integral; other abbrebnormalities as they occur in PAH and pulmonary
eno-occlusive disease (1,50,51) (Figs. 3C and 3D).
urthermore, the classic segmental perfusion defects
ay disappear in end-stage chronic thromboembolic
ulmonary hypertension (52). In nonthromboembolic
ulmonary hypertension, nonhomogeneous, patchy
erfusion abnormalities typically lack a lobar or seg-
ental distribution (Fig. 3D). In cases of large central
hrombi of Eisenmenger syndrome or in cases of
hrombi within major vessel pulmonary arterial aneu-
ysms of severe idiopathic PAH, perfusion scintigrams
emain nonsegmental (53).
ulmonary angiography. Pulmonary angiography
an be performed safely (54). Because of its supreme
bility to visualize even small pulmonary arteries,
ulmonary angiography is the gold standard of
maging thrombotic occlusions (Fig. 3 and Online
rements for the Diagnosis and Follow-Up of
Added Value Ref. #
Predictor of sPAP 50 mm Hg
Predictor of sPAP 40 mm Hg
3, 14, 15
Diagnosis of PH 16,17,18
Estimate of signiﬁcant RV systolic dysfunction
and predictor of prognosis
19
Predictor of sPAP 40 mm Hg 20, 30
Predictor of PVR 1,000 dyne/s/cm5
entricular; sPAP  systolic pulmonary arterial pressure.
hniques for the Diagnosis and Follow-Up of
Added Value Ref. #
Predictor of sPAP 40 mm Hg 20
For estimation of mean pulmonary
arterial pressure
34
HVF VTI) 55% Predictor of right atrial pressure
8 mm Hg
21
Predictor of mPAP 25 mm Hg 22
se Predictor of poor prognosis 23
nal Predictor of poor prognosis 34
fraction by 1% Decrease in GPSS by 14%, and LPSS
of RV free wall by 27%
24
Predictor of PVR 2.5 Wood units 25
Predictor of mean RAP 10 mm Hg 26
eak systolic strain; IVCT isovolumetric contraction time; IVRT isovolumetric
artery pressure; RAP  right atrial pressure; RVET  right ventricular ejectionasuTec
off
 d
crea
tudi
tion
bal p
naryviations as in Table 1.
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1290ideos 5 to 12). Although the magnitude of per-
usion defects generally leads to an underestimation
f vascular obstruction in chronic thromboembolic
ulmonary hypertension, angiography is generally
ble to depict thrombus at the subsegmental and
egmental levels, which is one of the criteria for
perability.
ultislice CT. Contrast CT angiography including
D rendering techniques shows whether arteries or
eins are primarily affected (Figs. 3A vs. 3C), and
epicts webs and bands, wall irregularities, stenoses,
neurysms, and complete vascular obstructions, as
ongitudinal Strain Analysis Using Speckle Tracking
t with normal pulmonary artery pressures and normal right ven-
) function and (B) patient with severe pulmonary hypertension
d RV function. (Aa, Ba) RV function using peak systolic longitudi-
Darker shades of red denote regions of better longitudinal func-
b) Corresponding strain curves. (Ac, Bc) Curved M- mode of peak
ain. (Ad, Bd) Segmental values for peak longitudinal systolic strain
right ventricle. See Online Videos 1, 2, 3, and 4.ell as bronchial collaterals (55). Bronchial arterynlargement has been positively correlated with
isease burden in chronic thromboembolic disease
56), but is not a reliable diagnostic criterion. CT
ngiography may help detect rare structural prob-
ems resulting from pulmonary hypertension, such
s aneurysms and dissections of pulmonary arteries,
s they may occur in Eisenmenger syndrome or
chistosomiasis, and left main coronary artery com-
ression by a large pulmonary artery (57).
High-resolution CT delivers images of the lung
arenchyma, allows exclusion of emphysema, bron-
hitis, and interstitial lung disease as well as infarcts,
ascular and pericardial malformations, and thoracic
all deformities. High-resolution CT may be helpful
or the diagnosis of pulmonary veno-occlusive disease
ith ground-glass opacities, interstitial edema, and
ilateral thickenings of the interlobular septae (58,59)
Fig. 3C). Perfusion inequalities, such as a sequela of
hronic thrombotic pulmonary artery occlusion (60)
nd other lung disease (61), manifest as a mosaic
arenchymal pattern with dark areas corresponding to
elatively decreased perfusion. Although a mosaic
attern is more common in chronic thromboembolic
ulmonary hypertension, it is observed in as many as
2% of patients with PAH (62). Exhalation sequences
an help exclude pulmonary vascular disease with
ccentuation of the darker regions of air trapping in
mall airways disease.
MR. CMR of the pulmonary vasculature is becom-
ng increasingly useful (63). Techniques include 2-
nd 3D contrast-enhanced CMR angiography,
MR perfusion (64,65), and phase-contrast imag-
ng. One area of investigation is circulatory changes
n the proximal pulmonary artery. Main pulmonary
rtery blood flow velocity at peak systole, maximal
ystolic main pulmonary artery cross-sectional area,
nd patient height and weight have been used to
alculate pulmonary arterial pressure (66). Main pul-
onary artery area distensibility and relative area
Table 3. Accuracy of Various Imaging Methods Against
Pulmonary Angiography as the Reference Method to Diagnose
Chronic Thromboembolic Pulmonary Hypertension
Method Ref. # Sensitivity, % Speciﬁcity, %
V/Q 46 90.0–100.0 94.0–100.0
45 96.0–97.4 90.0–95.0
47 100.0 86.0
CT 45 51.3 99.0
60 97.0 79.3
48 98.3/94.1 94.8
CMR 49 80.0 93.0
CMR  cardiac magnetic resonance; CT  computed tomography; V/Q Figure 1. L
(A) Subjec
tricular (RV
and reduce
nal strain.
tion. (Ab, B
systolic str
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1291hange, calculated as relative cross-sectional area
hange, predict mortality in patients with PAH (63).
At present, only limited evidence exists in sup-
ort of either CT or magnetic resonance angiogra-
hy for definition of thromboembolic obstructions
n chronic thromboembolic pulmonary hyperten-
ion (Table 3) (67,68).
oronary angiography. Conventional coronary an-
iography has become an important component of
iagnostic pulmonary hypertension imaging be-
ause of surgical treatment options, an increasingly
omorbid patient population, and a significant like-
ihood of coronary artery disease in the Western
opulation. Late-generation CT coronary imaging
ay replace invasive coronary angiographies in
uitable patients (69). Anatomic distortions due
o right heart enlargement and coronary-to-
ulmonary anastomoses are common.
urrent Recommendations
n most instances, echocardiography is the initial
ool to suspect pulmonary hypertension; never-
heless, invasive measurements remain indispen-
ible for the diagnosis and assessment of pulmo-
ary vascular reactivity (3). V/Q is a reliable and
ost-effective strategy to rule out chronic throm-
oembolic pulmonary hypertension. Starting out
ith V/Q (Fig. 2) may save the patient an addi-
Patients with Unexplained
V/Q S
Multidetector CT
CMR
and/or
Negative Indeterminate
CTEPH UncerCTEPH Ruled Out
At Le
Figure 2. Contemporary Diagnostic Imaging Algorithm
Radionuclide ventilation-perfusion scanning (V/Q) plays a key role in
Due to wider availability and more evidence, computed tomograph
Center-speciﬁc use of imaging modalities may vary. CTEPH  chronional catheterization procedure because hemody- iamic measurements can be performed concurrent
ith pulmonary angiography. CT and/or CMR are
sed as subsequent diagnostic imaging steps.
ollow-up is accomplished by echocardiography,
MR, and right heart catheterizations.
he Future of Imaging in Pulmonary Hypertension
ccurate visualization of complex RV anatomies by
dvanced imaging techniques and precise measure-
ent of blood volumes and flow may obviate
nvasive procedures in the future (70). In addition,
urrent concepts suggest that pathological remod-
ling occurs at the level of the pulmonary resistance
essels measuring approximately 100 m in diam-
ter. If one were able to visualize these small vessels,
ecognize occlusions, and ultimately also identify
ypertrophy of the smooth muscle cell layer, one
ight be able to predict the development of pul-
onary hypertension at early stages when hemody-
amics are still normal. Although current CT
echnology captures structures as small as 1,000
m, phase contrast CT depicts vessels in the range
f 100 m. Thus, early disease recognition is one of
he main challenges for future imaging. Such early
ecognition may allow for earlier preventive and
herapeutic approaches (71), which could ulti-
ately change the incidence and clinical mani-
estations of pulmonary hypertension as we know
lmonary Hypertension
n
Multidetector CT
Pulmonary
Angiography
and/or
and/or
CMR
CTEPH Likely
 1-2 Segmental Larger-sized Defects
ling out chronic thromboembolic pulmonary hypertension (44).
T) has been ranked before cardiac magnetic resonance (CMR) (3).
romboembolic pulmonary hypertension. Pu
ca
tain
ast
ru
y (Ct today (66).
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1292Figure 3. Completed Diagnostic Pathway of PAH Imaging Following the Diagnostic Algorithm Shown in Figure 2
(Aa, Ab, Ba, Bb, Ca, Cb) Examples of radionuclide ventilation-perfusion scanning (V/Q) labeled high probability under PIOPED criteria. In contrast, low-probability
V/Q of an idiopathic pulmonary arterial hypertension (PAH) case and corresponding diagnostic images are shown (Da, Db). (a) Technetium-99m–labeled aerosol
ventilation images are shown. (b) Technetium-99m–labeled macroaggregated human albumin injected perfusion images. (Ac–Af, Bc–Bf, Cc–Cf, Dc–Df) Classic
side-selective pulmonary angiography in the anteroposterior and lateral projections. Pulmonary angiograms were captured at frames that allow assessment of early cap-
illary ﬁlling. The respective anterior-posterior views of the pulmonary angiograms are also provided as Online Videos (Online Videos 5, 6, 7, 8, 9, 10, 11, and 12).
High-resolution computed tomography (CT) (Ag, Bg, Cg, Dg) and spiral CT angiography (Ah, Bh, Ch, Dh). (A) Images of a 65-year-old patient with chronic
thromboembolic pulmonary hypertension. Based on central thrombus location and a pulmonary arterial pressure of 70/27/45 mm Hg, with a cardiac output of
3.7 l/min, the patient was judged operable. Arrows indicate perfused lung tissue (bright opaciﬁcation), contrasting with unperfused areas (dark opaciﬁcation,
mosaic perfusion pattern (Ag). White arrows highlight fresh thrombus at the lower lobe artery take-offs (Ah). (B) Images of a 78-year-old female patient with
chronic obstructive pulmonary disease Gold stage III. Invasive pressure measurements demonstrated elevated pulmonary arterial pressures of 115/44/68 mm Hg,
with a cardiac output of 3.2 l/min. Despite a high-probability V/Q (Ba, Bb), pulmonary angiography was completely normal (Bc to Bf). Right lower lobe attenua-
tion was due to atelectasis of part of the lower lobe and pleural effusion (Bg, Bh, arrows). (C) Images of a 52-year-old male patient with pulmonary veno-occlu-
sive disease. Invasive pressure measurements demonstrated mildly elevated pulmonary arterial pressures of 49/25/38 mm Hg, with a cardiac output of 4.7 l/min.
As substrate for the high-probability lung perfusion scan (Ca, Cb), pulmonary angiography showed a territorial lack of the capillary ﬁlling phase (Cc–Cf). Pulmo-
nary arteries were narrow but smooth. Arrows indicate Kerley B lines (Cg). White arrows point to obliterated pulmonary veins close to the entry into the left
atrium (Ch). (D) Images of a 47-year-old male patient with idiopathic PAH. Invasive pressure measurements demonstrated pulmonary arterial pressures of
59/22/36 mm Hg, with a cardiac output of 4.23 l/min (cardiac index of 1.5 l/min/m2). (Da, Db) Low-probability lung V/Q with some nonsegmental patchiness on
perfusion (Db). High-probability scans have been reported in 0.01% of PAH cases (45). Although perfusion scans in idiopathic PAH may show certain abnormali-
ties, the presence of 1 segmental or larger perfusion defects should suggest the diagnosis of potentially correctable, major-vessel chronic thromboembolic pul-
monary hypertension. Note the pruning of peripheral pulmonary arteries (Dc to Df). No mosaic pattern was seen by high-resolution CT (Dg).
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